Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Nivolumab in HCC
NCT03418922Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenvatinib and nivolumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Dose-Limiting Toxicities, Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events up to 53 months and 6 more. Started Jan 2018; status: completed.
02
Drugs
lenvatinibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03418922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418922.